Good afternoon. My name is Regina, and I will be your conference operator today. At this time, I would like to welcome everyone to the second quarter 2025 Agilent Technologies, Inc. earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. To withdraw your question, press star one again. Thank you. Parmeet Ahuja, you may begin the conference.

Thank you and welcome everyone to Agilent's conference call for the second quarter of fiscal year 2025. With me are Poring McDonald, Agilent President and CEO, and Bob McMahon, Agilent Senior Vice President and CFO. Joining the Q&A will be Simon May, President of the Life Sciences and Diagnostics Markets Group, Angelica Ryman, President of the Agilent CrossLab Group, and Mike Zang, President of Applied Markets Group. This presentation is being webcast live. The press release for our second quarter financial results, investor presentation, and information to supplement today's discussion, along with the recording of this webcast, are available on our website at www.investor.agilent.com. Today's comments will refer to non-GAAP financial measures. You will find the most directly comparable GAAP financial metrics and reconciations on our website. Unless otherwise noted, all references to increases or decreases in financial metrics are year-over-year and references to revenue growth are on a core basis. Core revenue growth is adjusted for the impact of currency exchange rates and any acquisitions and divestitures completed within the past 12 months. guidance is based on forecasted exchange rates as a reminder beginning in the first quarter of fiscal 2025 we implemented certain changes to our reporting structure related to the reorganization of our three business segments we have recached our historical segment information to reflect these changes and have provided the financial details on our website these changes have no impact on our company's consolidated financial statements. During this call, we will also make forward-looking statements about the financial performance of the company. These statements are subject to risk and uncertainties and are only valid as of today. The company assumes no obligation to update them.

Please look at the company's recent SEC filings for a more complete picture of our risk and other factors and now i'd like to turn the call over to poric hello everyone and thank you for joining today's call agilent delivered strong second quarter results in a highly dynamic market environment revenue of 1.67 billion dollars for the second quarter represented growth of six percent reported and up 5.3 percent core compared with the second quarter of 2024. Operating margin was a solid 25.1% as we absorbed some incremental tariff costs. We also delivered EPS of $1.31, growing 7% compared with the second quarter of 2024. Both revenue and EPS exceeded our expectations, marking the fourth consecutive quarter of accelerating growth. Our performance was driven by growth across markets and regions, speaking to the diversity of our business. We also saw another quarter of building momentum in instruments with our book-to-bill ratio again greater than one. Thank you to the Agilent team for delivering these results by tirelessly going above and beyond for our customers. No matter where I travel in the world, our customers consistently say the same thing. The Agilent team is second to none and for that reason they want to increase their partnership and collaboration with us even more, even during a challenging macro environment. These conditions have proved the efficacy of our three-year Ignite transformation, which is the execution of our strategy. We're already leveraging Ignite to create an enterprise operating model that has resulted in multiple early wins, including tariff mitigation. More on that in a moment. First, let me tell you why our Q2 was so strong. All regions grew in the quarter, Americas grew low single digits, EMEA grew mid single digits, and China led the way at 10% growth, exceeding our expectation, while the rest of Asia grew high single digits. China saw stable demand conditions sequentially, while a favourable Lunar New Year comparison helped year-on-year growth. In Asia, India delivered high teens growth. India is a long-term, high-growth, innovation-driven market, which is why we've opened our first India Solution Centre there this month. The centre showcases Agilent's expertise across disciplines to deliver end-to-end solutions in sectors such as GLP-1 analysis, emerging food and environmental contaminant analysis, and PFAS detection. We also delivered mid-to-high single-digit growth in all end markets except academia and government which declined modestly with strong results in Asia moderating the expected softness in the US. Pharma grew six percent at the high end of expectations led by small molecule growing low double digits. Biopharma continues to recover at a slower pace growing low single digits as we continue to see funding challenges in small and mid-sized biotech, primarily in the US. Within Biopharma, NASD was a standout growing high single digits in Q2, and we're looking forward to double-digit growth from NASD in the second half of the year. In addition, while not yet part of core growth, our BioVectra business performed well, exceeding guidance. BioVectra's capabilities are in the sweet spot of tremendous markets, For example, GLP-1s and Compex Chemistries, with terrific medium and long-term growth potential. We are very excited about the combined offerings of NASD and BioVectra. Diagnostics and clinical grew 8% ahead of expectations on strong performance of our pathology business in the Americas and Europe. Environmental and forensics grew 6% on strong PFAS testing demand globally. PFAS testing remains strong for Agilent globally, and we see it continuing to expand into other end markets, such as food and chemical and advanced materials. In Q2, PFAS grew more than 70% year-over-year globally, with Europe and China more than doubling their business. PFAS provided an incremental 80 basis points to our growth in the quarter, and it's now annualizing to well over $100 million. We continue to be very optimistic about the long-term growth prospects globally in PFAS as regulations and standards continue to be put in place. For PFAS testing, our Infinity 3 and our 6495D system is the most sensitive and robust solution. The Agilent team has deep understanding of customer challenges and how we can help them with their testing needs through delivering integrated workflow solutions, productivity, and new modality application development. We are tracking over 350 regulations globally and are very confident in the continuing momentum in this emerging 1 billion dollar addressable market by 2030. In chemicals and advanced materials revenue grew 4% with high single digit growth advanced materials while chemical and energy was up low single digits globally. Overall we saw growth ex-China offset by low single digit decline in China. Lower oil prices are net positive to the CAM business given it drives lower input prices to our chemical business which is four times bigger than energy. FU grew 8% benefiting from strength in Asia through government-funded technology refresh. Our smallest end market, academia and government, declined only 2% in the quarter, better than expected performance in the US and globally. Given we were ahead of others talking about potential US funding impacts in our first quarter earnings call and did better than expected in q2 we feel we already have adequately captured any variability looking forward when looking holistically across agilent we continue to make investments in our digital ecosystem such as our next generation e-commerce platform so that we can offer an outstanding customer experience those investments are paying off as we grew digital orders by 12 year-over-year to 295 million dollars i also want to highlight acg's nine percent growth this quarter, which exceeded expectations. ACG's performance was led by strong growth in automation, services, and consumables. For the first time in several quarters, we saw both on-demand and installation services return to growth. These results keep us on track with the long-term commitments we outlined at our Analyst Investor Day in December, including 5% to 7% core revenue growth, expanding margins 50 to 100 plus basis points annually, and driving double-digit EPS growth. We have momentum at Agilent. Over the past 12 months, my first year as CEO, the Agilent team has accomplished a lot. We've built a formidable senior leadership team that is working in lockstep to maximize Agilent's resources to drive shareholder value. We've evolved our enterprise strategy to be market first and realigned our businesses to our markets. We acquired BioVectra for roughly $1 billion to expand our CDMO capabilities. and we have moved from planning to execution in Ignite. Before providing further details in Ignite, I want to pause here and thank our Agilent team members for how quickly they have adapted to change and the company's higher ambition. It is no small feat to transform a company, and I've been impressed by our colleagues' passion for our mission and vision, and their increased zeal to delight customers so that Agilent continue to win in the market. These team members are leading Ignite and an initiative that is already yielding incredible results. Those incredible results include strengthening our strategic pricing capabilities and implementing enterprise-wide pricing initiatives. In six months, we already have exceeded the full-year price contribution from last year and are expecting at least 100 basis points of price realization in 2025, with expectations for an even greater impact in 2026 and beyond. Improving organisation agility and efficiency by flattening management layers and increasing spans of control by 30% to improve our organisation's health and become a nimbler company. Additionally, we expect this to deliver annualised savings of about $80 million starting in the second half of the fiscal year. Centralising our procurement under a Chief Procurement Officer and adopting an integrated enterprise-wide approach to vendor management. We already see strong momentum exceeding our internal savings targets, ramping in the second half of this year, while being essential in mitigating tariff expense with our suppliers. This is with projected procurement annualized savings exceeding $50 million by the end of 2025 and establishing a strong foundation for additional gains in 2026. Ignite has become the backbone of our operating system, enabling faster decision making more scalable growth and over 130 million dollars of profit for fiscal year 2025 it is our institutional engine for long-term value creation center to value creation is our continued commitment to innovation i'm proud to share three impactful new products that demonstrate that commitment in our cell analysis portfolio we just launched the seahorse xf flex analyzer with its world-class leading sensitivity versatility intuitive design, and compatibility with 3D models, the XXFlex empowers more researchers than ever before to explore cellular metabolism with confidence. And at the 73rd ASMS conference next week, we will launch our latest innovation in liquid chromatography mass detection. Our new Infinity Lab Pro IQ series offers unparalleled sensitivity, speed, and efficiency, making it the ideal choice for customers analyzing complex biomolecules in settings where performance and lab productivity are key at asms we will also showcase our enhanced 8850 gc now coupled with the power of our market leading bcms that enables our customers to do more with less we've reduced the 8850's footprint by 50 and increased throughput up to five times by lowering its energy usage by 45 compared with a conventional benchtop gc we also continue to have success with our infinity tree lc in orders funnel and our attached rates of service and consumables we're seeing this success both geographically with robust growth in india a particular highlight and across all in markets with our top customers calling out the infinity tree superior performance intelligence and task automation capabilities to help further drive agents internal and external innovation engine i'm delighted to announce august spec is joining Agilent next month as our Chief Technology Officer. August has spent over 25 years in senior R&D roles in the life sciences industry. Welcome, August. Ignite also gave us a significant head start on tariff mitigation, enabling the immediate creation of our Tariff Task Force that has allowed us to make changes that will maintain our market strength regardless of tariff rates. We are proactively managing tariff exposure by taking several targeted actions, including focusing on specific product lines and production sites rather than adopting a one-size-fits-all approach, further diversifying our supply chain by leveraging our extensive global sourcing capabilities and manufacturing network, ensuring we're geographically even closer to customers, implementing strategic pricing initiatives around the globe that protect our market competitiveness. While we remain vigilant amid geopolitical developments are localised manufacturing, proactive tariff mitigation and a diversified customer base gives us greater resilience and agility globally than many of our peers. Through our tariff task force, enabled by our Ignite operating model, we feel that we are able to mitigate most of the impact in 2025 and fully mitigate in 2026, even when considering recent developments on the US-EU tariffs. With the task force, we can create targeted analytics in a matter of hours not days that identify key supply chain and commercial opportunities that will allow us to maximize our tariff mitigation efforts. Our top priority is ensuring we minimize tariff impacts on our customers and that our customers have the trusted Agilent products, solutions and services they need. Looking ahead we are confident that the long-term fundamentals and secular growth drivers of our markets remain strong. For the year we are maintaining our core growth rate of 2.5 to 3.5% while incorporating favourable currency movements. And leveraging our IGNITE programme, we are fully absorbing all unmitigated FY25 tariff costs and maintaining our full year EPS guidance. While our results this quarter exceeded expectations, we believe it's important to remain disciplined in our outlook given the ongoing uncertainty in the macro environment and geopolitical landscape. We are committed to maintaining guidance that is both credible and achievable, and we continue to prioritize long-term value creation. Bob will now share further details about our Q2 and guidance. Bob.

Thanks, Parag, and good afternoon, everyone. In my remarks today, I'll provide additional details on revenue in the quarter, as well as take you through the income statement and other key financial metrics. I'll then cover our full year and third quarter guidance. As Porig mentioned, Q2 revenue was $1.67 billion, above the high end of our guidance. On a core basis, we posted growth of 5.3% while reported growth was 6%. Currency had a negative impact of 1.6%, which was half a point better than estimated as the dollar weakened during the quarter. M&A also contributed 2.3 percent, coming in nicely ahead of expectations. Now let me talk about our performance by business group. The Agilent CrossLab group reported revenue of $713 million, growing 9 percent, which was ahead of our expectations. Double-digit growth in consumables and automation and high single-digit growth in services drove ACG's performance. Our life sciences and diagnostics market group reported revenue of $654 million in the quarter, growing 3%. Core growth was driven by our pathology business and NASD, both which delivered high single-digit growth, and our LC and LC-MS instruments that grew mid-single digits. Our cell analysis business returned to growth up low single digits. Performance was partially offset by an expected mid-single-digit decline in our NGS business. And our Applied Markets Group reported $301 million in the quarter, flat versus last year on a core growth basis. Growth in spectroscopy and GCMS was offset by some timing-related declines in gas chromatography. Before getting into the rest of the P&L, I want to cover additional details on Q2 revenue that were influenced by the April tariff announcements, primarily in China. While there was no revenue impact to Agilent overall, we did see some shifts by group in the quarter. Specifically, we saw roughly $15 million of in-country ACG lab consumables revenue pulled forward into Q2 from Q3. However, this was offset by longer processing time through customs on some select instrumentation in both AMG and LGG. Again, this did not impact our overall revenue for Q2 or our Q3 outlook, but we have taken that into account by group looking forward, which I'll talk to in a minute. It is also important to note we've seen a return to normal customs processing times here in May. Now, let's move on to the rest of the P&L. Gross margin was 54.1% in the quarter, roughly in line with our expectations after accounting for 55 basis points of incremental tariff costs. It is down versus last year, with the delta being equally distributed among tariffs, currency, and product mix. We drove operating margins of 25.1%, while flat versus last year, excluding the 55 basis points of incremental tariffs, it would have been an increase year on year. So, overall, a strong showing. Below the line, we had $2 million of income, while our tax rate of 11.5% was better than expected. And we had 285 million diluted shares outstanding in the quarter. Putting it all together, Q2 earnings per share were $1.31. That was ahead of our expectations and up 7% from a year ago, growing faster than core revenue. This is a very good result in the face of the dynamic macro environment, which is a testament to the Agilent team forging close collaborative partnerships with our customers. Now, let me turn to cash flow and the balance sheet. Operating cash flow was $221 million in the quarter, and we invested $114 million dollars in capital expenditures. We purchased 165 million dollars in shares and paid out 70 million dollars in dividends during the quarter. And we ended the quarter with a net leverage ratio of one, so we continue to have a very strong balance sheet. Now let's move on to our outlook for the fiscal year and third quarter. As Porig mentioned earlier, we are maintaining our core growth outlook for the year and increasing our reported revenue guidance by 50 million dollars to reflect incremental FX benefit since our last guide. This results in an increase to our full-year reported revenue to be in the range of $6.73 billion to $6.81 billion, increasing reported growth to 3.4 to 4.6%. Currency is now expected to represent a 1.1 percentage point headwind for the year versus a prior 1.9% headwind, while our M&A guidance is unchanged at plus 2 to 2.2 percent revenue impact for the year. Core growth is still expected to be between two and a half to three and a half percent for the year. We believe this is a prudent way to manage considering the dynamic macro environment. Now, to help you with your models, I wanted to provide some additional perspective on our end markets. In pharma, we are monitoring the progress of U.S. pricing policy proposals, but are not seeing a change in customer behavior. As a result, we continue to expect low to mid single digit growth for the year, with the second half of the year continuing to show steady improvement versus the first half. For diagnostics and clinical, given Q2's performance, we now expect growth to be towards the upper end of mid-single digits. And we expect growth for both chemicals and advanced materials and food to continue to be in the range of low to mid-single digits, while the environmental and forensics market is a solid mid-single digit growth on PFAS strength. And lastly, as a reminder, academia and government is our smallest market at 8% of total revenue, with NIH-related research representing only about 1% of revenue. We are maintaining our outlook from Q1 of a mid-single-digit decline in total, with the U.S. market being the driver. While we perform much better than we expected in Q2, we feel this is a prudent approach for the year. We are also maintaining our full-year EPS guidance of $5.54 to $5.61, while covering the incremental tarot costs that I'll explain in more detail in a moment. This represents a year-on-year increase of 4.7% to 6%. For clarity, let me briefly summarize the tariff assumptions we've incorporated into our FY25 guidance. Based on the tariff rates that are currently in place, we estimate that the gross incremental tariff exposure in the second half of our fiscal year is $50 million. This is on top of the roughly $10 million we have already absorbed in the first half of our fiscal year. 30% of the exposure is represented by trade between the U.S. and China, about evenly split. Of the remaining 70%, 30 percentage points is from the E.U. into the U.S., and the remaining 40% is from the rest of the world into the U.S. As Porig mentioned, we have mobilized our team using the IGNITE operating model to quickly move our procurement and supply chains to minimize the tariffs and build inventory. We are using the combination of supply chain moves, like moving LC production into the U.S., surcharges, and some of the IGNITE-driven savings that Porig previously highlighted to offset the incremental costs. Importantly, we expect our actions to fully mitigate the costs in fiscal 2026. The tariff landscape continues to be dynamic and hard to predict. However, given the recent news of potentially increasing tariffs on EU source products to 50% as early as July 9th, we felt it important to frame that exposure. If implemented on July 9th, we estimate that would add another $40 million in gross exposure in the second half of the year. But through additional pricing mitigations and the inventory we've built up, we anticipate the net impact would be minimal for the year. This is the power of our tariff task force. It enables us to address tariffs at the enterprise level and align Agilent's key senior leaders so we can quickly leverage our strong and diverse supply chain footprint and adjust to the market-driven approach of our unified commercial team. Finally, for your modeling, we are now projecting an increase in other income and expenses to $15 million in income, along with a 12% tax rate for the year and 285 million diluted shares outstanding. Moving to the third quarter, we are guiding to revenue of $1.645 billion to $1.675 billion. This range represents an increase of 1.7 to 3.6% growth on a core basis and an increase of 4.2% to 6.1% growth on a reported basis. Currency is a 0.6% tailwind, and M&A impact is expected to be a 1.9% benefit in the quarter. Again, while the Q2 stocking and logistics dynamics I mentioned earlier do not affect the total revenue in Q3, we do see it playing out differently by group. For that reason, we thought it helpful to provide a perspective on group core growth guidance in Q3. Given the Q2 impacts, we see LDG growing mid-single digits and both ACG and AMG growing low single digits. Third quarter non-GAAP earnings per share are expected to be between $1.35 and $1.37, representing growth of 2.3 to 3.8%. Now I'd like to turn the call back to Porig for closing comments.

Porig? Thanks, Bob. Before I close, I want to thank our retiring board member, Heidi Coombs, for many years of service with Agilent. And I want to welcome Pascal Sariot and Judy Gallick-Brown to the board. Pascal is CEO of AstraZeneca and Judy is currently founder and CEO of Downtown Advisory after holding senior leadership positions at Amgen and Perigo. Both bring decades of global leadership experience from the pharmaceutical, biotechnology and healthcare sectors with a proven track record in strategy, innovation, operations and finance. I look forward to working with you both. It's an exciting time to be part of the Agile and Growth story, to be part of building on our foundational strengths of being an established leader in 80 billion dollar markets driven by secular growth, having leading market share and sustainable competitive advantage to our intense customer focus and re-accelerating growth through innovation and market share gains. And we continue to look at the long term. As Bob mentioned, we have a strong balance sheet and remain focused on augmenting our internal innovation with external growth opportunities. We have a robust pipeline of opportunities of all sizes that are aligned with our strategy we explained in December and will further build this great company. In a highly dynamic macro environment, Agilent is excelling. We remain confident in our ability to deliver on our full year 2025 commitments and in our long-term trajectory towards financial framework we explained at Investor Day. With Ignite scaling and our pace of innovation accelerating, Agilent is well positioned to outperform regardless of the near-term market dynamics. After one year as CEO, I'm even more energized by what we're accomplishing at Agilent, and we're only getting started. Thank you for your attention. I now hand it over to Parmeet to kick off our Q&A. Parmeet? Thanks, Farik.

Regina, if you could please provide instructions for Q&A now.

At this time, I would like to remind everyone, in order to ask a question, press star, then the number one on your telephone keypad. Our first question comes from the line of Patrick Donnelly with Citi. Please go ahead.

Hey, guys. Thank you for taking the questions. Maybe one just on the order trends that you guys saw in the quarter. Can you just give us some color how those progressed as the quarter progressed? I mean, you guys are unique with the timing. Probably saw a little bit of the pharma tariffs, the actual tariffs come in. Just curious, you know, if you're willing to talk about April, certainly, you know, May would be welcomed as well. But, you know, what you saw on the order front, did you see any pull forward around the pharma tariffs?

I know you talked about the ACG pull forward on the consumables, but just curious what you were hearing from customers and again what you thought on the order front versus the revenue side would be helpful as well yeah thanks patrick so i can i can start here so first of all our book to build was greater than one um and our orders grew uh low single digits in q2 and overall for the for the first half orders grew mid single digits so in terms of any pull forward from pharma we haven't seen anything and we've seen actually very stable business uh across across the regions of course as bob talked about in the script we did see a pull forward and consumables but that comes out on the wash given some of the issues we had with with customs etc in April but that's back to normal now. So what I would say is peak pharma customers are in particular still spending on key projects and the replacement cycle continues and so no changes there and we do expect that this gradual recovery to continue in the second half.

Okay that's helpful and then maybe just on the NASD bio vector piece you know sounds like those performed quite well in the quarter. Can you talk about, I guess, expectations for the rest of the year? It sounds like NASD is maybe creeping a little bit higher, which is great. Can you talk about the visibility there? I know sometimes you get orders, you know, well out a few quarters. I mean, are you into 26 on some of these order books? Maybe just talk about the visibility and what you're seeing in those businesses would be helpful. Thank you, guys.

Yeah, I'll start and I'll hand it over to Simon. So first of all, really, really pleased by the progress in our CDMO business and NASD with high single-digit growth and with BioVectra into high teens, you know, we're seeing the combination of these businesses right in the sweet spot of really important therapeutic areas coming together. But I'll hand it over to Simon for more color on that.

Yeah, I'd say overall in the CDMO businesses, we were pleased on a couple of major fronts for the quarter just passed. We saw progression of some early commercial programs in the NASD business. We talked about that. few times previously we're now starting to see the revenue mix there evolve more from 50 50 towards 60 40 in favor of commercial we think that bodes well for the future and then in the buyer vector business there was also some really noticeable progress our glp1 manufacturing programs we saw successful scale up there we saw some nice process efficiency gains and that's now beginning to become a pretty meaningful contributor to the CDMO business overall. As we think about going forward in the near term, I'd say we're pretty confident about the second half of the year. As we look at NASD in particular, we've got a very clear line of sight to the double-digit growth that was mentioned in the script. I'd say we've got the orders in-house that we need to fulfill that. And then longer term, we continue to think we're extremely well-positioned in this space. And again, these combined capabilities of NASD and BioVectra really put us in the sweet spot of advanced therapeutic modalities and particular areas that really excites us, like oligos and antibody drug conjugates. And bioconjugation generally is a really high growth area where we've got real strong capability in BioVectra. So a lot to be pleased about in the quarter. As always, I'd caveat it. This business is lumpy. it will continue to be lumpy, but we're on a clear upward trajectory here. We feel like we're nicely positioned, and we've got a good line of sight for the rest of the year.

Great. Thank you, guys. Thanks, Patrick.

Our next question comes from the line of Jack Meehan with Nefron Research. Please go ahead.

Thank you. Good afternoon. I wanted to follow up on Patrick's first question just around the end quarter impact you saw on ordering just around the tariffs. The 15 million of consumables that got pulled forward, what were you hearing from customers as to just the reason for why that happened? Just curious about that. And then on the instrument side, does the guide assume you recapture that in the fiscal third quarter, or do you think that could come later in the air.

Yeah. Hey, Jack, this is Bob. I'll take that. And as you can imagine, in China, given the high tariff rates that were being proposed at the time at mid-April, there was a desire to try to get ahead of that from some of our customers. And we had inventory in country. And so we just saw some stocking of orders that would normally be throughout Q3 being pulled into Q2 and being delivered. On the flip side, because of the changing tariffs, there were a number of longer delivery times and logistics activities that were happening at the ports in China as well that primarily impacted our instrument business because we bring those in. And so that offset in total that in China. And so when we look at that, we would expect no change. We didn't see any change to our overall revenue in Q2, just some moves between instruments and consumables. And that will reverse itself, we expect here in Q3. But again, in total for Q2 and Q3, the total results are fine.

Got it. That makes sense. And I think that explains where I was going to go with my second question as to why China was much better than I was thinking. So I do have one other follow-up, which is, Bob, just can you boil it all down now on the margin side for the year, kind of what the guide implies for operating margins?

Yeah. So the margin, given obviously the cost associated with the incremental tariffs, we are covering that with a combination of of tariff mitigation activities as well as some pricing surcharges and then some of the Ignite. But given the impact of that, it'll be closer to flat versus year ago. If you took that out, we would still be on track for the margin expansion, similar to what we saw here in Q2 as an example. So we were flat year on year. But if you took out that 55 basis points, we'd been right on track. So we still feel good about that cadence going forward, particularly when we talk about 2026, when we when we talk about mitigations, that means that we will eliminate the gross impact of the tariffs through through some of the supply chain moves that are already ongoing. Okay, thank you.

Our next question comes from the line of Matt Sykes with Goldman Sachs. Please go ahead.

Hi, this is Evian for Matt. Thanks for taking my questions.

So the first one, in the past you've noted that the majority of your exposure within your pharma business is in clinical versus earlier stage research uh have you seen any differences between the ordering patterns of these two applications especially with the recent uncertainty in the research spend from these customers yeah no i would say the lion's share of our business is actually on the qaqc and development side and we saw small molecule actually grow 10 percent in the quarter was which was a fantastic result um so we we see across pharma that actually that's the part that's more resilient uh currently and particularly in the future where you see potential reshoring that may happen over over a few years of course um qaqc testing benefits from that and of course benefits by the way from from supply chain changes with pharma around the globe as they look to mitigate things themselves so overall i would say a very strong quarter on that side and we continue to expect. We do actually, of course, serve our customers on the R&D side and the development side, but the vast majority would be on the QAQC side.

Okay, great. And then within PFAS, we've seen some potential easing of regulation within water in the U.S. Have you seen this impact orders as customers work through the uncertainty?

And then how much can growth in food and product testing offset potential weakness in the water regulation? yeah so first of all you know just a tremendous result in pfas and q2 we grew 75 year over year and um also saw tremendous growth around consumers and connect rates with our systems uh just to give a little bit of color as well europe and china led um really really grew well and of course with emia so lots to like about it if you think about some of the recent announcements it's actually uh very very it's sometimes it's hard to get some of the details and those announcements with the restructuring that's going on. But I think you're going to see the water testing continue over the next few quarters, especially in the broader area outside the US. I think the larger part of our PFAS business in the US over the next year or the next half is going to come from industrial-based testing that's around wastewater, soil and discharges. That's where you see people worried about litigation. You see a lot from the EPA coming out, you know, to pay for any infringements. So we also see that material testing globally and water testing in EMEA, APAC, to drive business over the next two quarters. So I would say we're expecting very strong results for the year, but beyond the year, extremely, extremely strong as well. There's also one emerging thing that's coming up quite a bit is that PFAS testing is going to start more into air and volatile PFAS, which is right in our sweet spot for GCMS. Currently, that's about, I would say, 2% to 3% of the market. But over the next 12 to 18 months, we expect that to go to 8% to 12% of the market, where we will have a very high market share win rate on that. So that gives a color around PFAS. Great. Super helpful.

Thank you.

Our next question comes from the line of Rachel Voddenstahl with JPMorgan. Please go ahead.

Great. Good afternoon. Thanks so much for taking the questions. So I wanted to follow up on your comments there on Evie's question regarding reshoring. You've had a few of your peers call this out as a potential tailwind, just given the number of capacity announcements that we've heard from pharma companies in recent months. So can you walk us through, have you had any concrete conversations with customers regarding these capacity buildouts? And how do we think about the timing of when we could see any tailwinds related to onshoring?

Yeah, great question, Rachel. So having spent, you know, three decades in this industry and actually the earlier parts of those decades in Ireland when there was a lot of pharmaceuticals being built in Ireland in terms of capacity, generally the way these things happen, it takes quite a bit of time. What we're leading with is our strategic account program. So we're at the very highest levels with our pharma customers. Discussions are extremely early, so I wouldn't say any concrete out of that yet. But generally what happens is, you know, you see the, you know, the plans for the site being put up. You also see qualification plans for the site. Generally, construction tenders are out. And then from the construction tenders, people think about lab capacity. And that is the point which is really critical to be in. And we feel very good about our position with the strategic accounts. Also, by the way, you hear of Methix moving early, you know, so maybe it moves from EMEA to the U.S. so we find out from our large install bases where those methods are going to go. But we don't expect anything. I would say you're going to see something maybe at the end of two to three years, but it will be a tailwind for us given the amount of systems and also the proportion of QA, QC in those systems.

Great. And then just for my follow-up, I wanted to ask on pricing. Can you talk about your ability to pass on price in this environment given the dynamic environment that we're seeing in light of tariffs and in general, what's embedded for pricing for the rest of the year and for guidance. Thanks.

I'll take the first part and I'll give the second part to Bob on it. So, you know, we have enterprise pricing capability that we build through Ignite. So we do it in a very, we do surcharges in a very structured way.

We actually, clearly we're looking at our competitive situation around in different regions and making sure we're staying focused on the customers so based on the work we're already optimizing our pricing and we have it has been a it's been a it's been a it's been a it's been a quite a big part of our mitigation going forward but Bob I don't know if you want to talk about guide yeah hey Rachel this is Bob to build on what Porek said just to reiterate what we said in the prepared remarks we've already achieved what we achieved all of last year through the first six months of this so a very good performance there if you recall in our guide we had about a hundred basis or not we had 100 basis points of price were on track for that for the year probably a little bit higher with that with the pricing mitigation activities that are being established as a result of tariffs as you can imagine depending on the competitive nature there the type of pricing that we would have vis-a-vis the supply chain activities which would be a permanent mitigation we're balancing all all of those as well as the ignite pricing activities as well or excuse me savings activities. So we are not taking all of the mitigation from tariffs out of price. We think that is something that will help us with our customers as well, and looking to move things around to have what we would call internally kind of no regrets moves to be able to manage our supply chain globally, given the dynamic nature of how these rates are moving back and forth. So So that's kind of how we're thinking about the second half of the year. And again, in 2026, we would expect to have all of the tariff rates being mitigated.

Our next question comes from the line of Puneet Suda with Lear Inc. Partners. Please go ahead.

Hi, Poreg and team. Thanks for taking my question. First one on the replacement cycle. You talked about book to bill being more than one. Just trying to understand, how should we think about the Infinity 3 replacement cycle? How is it doing in the environmental labs versus the pharma labs? What are you seeing in the field? Early traction, maybe just help us understand how should we think about the anatomy of this replacement cycle for Agilent?

Yeah, I'd be happy to go through some details. So the Infinity 3 ramp continues extremely well. we see a lot of very strong adoption and customer feedback continues to be very positive our order funnel is really growing nicely with the infinity tree and uh we we def we're really pleased with market acceptance what we're actually seeing with infinity tree under replacement cycles we're seeing actually a higher connect rate and service and consumers with that system which really bodes well for the future but overall replacement cycles on the lc side i'll focus on that first and then maybe talk to the broader and broader portfolio and we've been you know we've been seeing a continuous ramp on that we expect that to continue over the next few quarters we have thousands of 1100s we have 1260 1290s we're moving through that that replacement cycle but of course it doesn't happen in one quarter it doesn't happen sequentially quarter after quarter you see it gradually build and generally um i would say the funnel to close is about you know six to nine months to close an LC order. So we continue to see that increase, but very pleased with the adoption. And of course, there's a much broader continuum around our replacement cycle, giving our GCMS and our LCMS install bases that are already, I think, continuing to start to replace.

Yeah. Hey, Porg, just to build on that, just to reiterate some of the proof points that you talked about when we talk about small molecule QAQC, which is the lion's share of the installed base that grew double digits in Q2 from a revenue, you know, all in inclusive of service consumables and instrumentation. So, it speaks to the full workflow solution. And to your question about environmental, that's our sweet spot, and we grew in PFAS over 70%. So, I think it can kind of tells how well that's being adopted in the environmental space as well.

Got it. And my follow-up is, can you size, you know, how much of the China growth in the quarter was from the sort of the Lunar New Year timing perspective, how Lunar New Year played out this year versus last year versus the sort of the consumable pull forward that you saw? And what was the China stimulus in the quarter? Thank you.

Yeah, I'll start on that, Puneet. So, the pull forward of the consumables that we were talking about actually had nothing to do with Lunar New Year. It was really driven by the tariffs. So, that, I think, is an idiosyncratic activity that wouldn't continue. The Lunar New Year played out the way we expected it to for the full year guide. So it was roughly about two points of total company when you look at the change year on year. And it kind of played out the way we expected it to. And so, you know, if you look at our revenue dollars in China sequentially, it's actually a very good performance. You know, still well above $300 million speaks to the stability in that market. And in terms of the last question that you had around stimulus, you know, we continue to be pleased about the performance. If you looked at the applied markets, we had some very good performance in food, some of the other applied markets. Most of our stimulus was actually in Q1, but we're very optimistic about the funnel activity right now for the next stimulus, which we are starting to work with our customers and putting together bids for the second half of this year, probably will be revenue at the end of our calendar year here, potentially in Q4. That would be upside if it is in Q4. We haven't built that into our numbers, but I feel very optimistic about our ability to do that, given our made-in-China capabilities.

Got it.

Okay.

Thank you.

Our next question comes from the line of Vijay Kumar with Evercore ISI. Please go ahead.

Hey, guys, congrats on a nice execution here, and thanks for taking my question. Maybe my first one on the guidance here, you look at ACG, I think actually pull forward, it was still a pretty healthy 6+, maybe high signals kind of number. Why is it slowing down to low signals, I think you said, in CQ. And when you apply that to overall company, I think it's stepping down by 250 basis points sequentially. I know like on a year-on-year basis, like the comps maybe explains it, but on a stack comp basis, it looks maybe a little conservative. So maybe talk about the third quarter assumptions.

Yeah, thanks. I'm going to hand over to Angelica now to give some color on that one.

Yeah, thanks for the question. You know, I think coming back to the tariff-related consumables pull forward, right, we made those adjustments. And so once we make those adjustments for the quarter-on-quarter growth rates and normalize them, you know, the guide is in the mid-single-digit range. So that's really accounting for it. But when you look more holistically, the fundamentals of ACG remain incredibly strong as we look towards the rest of the year. We're well positioned to continue to support customers as they're maximizing the assets in their laboratory through the broad portfolio, whether that's consumables, services, as well as some of the other offerings in the ECG portfolio. So, we just adjusted and still a healthy growth rate across ECG for a full year.

Understood. And then maybe one on the P&L, I think on the margins, I thought I heard you say gross margins was in line, but it looks like versus three, maybe numbers came down, sequentially gross margins were down. Maybe talk about what happened on gross margins, was there a mixed impact? And I think you had a restructuring charge, which wasn't there in prior quarters. Is there some new cost actions that Aislinn has initiated? Thank you.

Yeah, when we were talking about the gross margins, if you look at it year on year, we did have the unplanned tariff activity, which was about 55 basis points in gross margin that hit in Q2. If you look at it versus a year ago, there was a combination of tariffs, product mix, which we had incorporated, as well as some currency-related activities. So feel good about kind of where that is. In terms of restructuring, that's probably more on a GAAP basis, Vijay, and we would have taken that out for the numbers that I was just referencing on a non-GAAP basis, but that would have been part of some of the organizational health activities that Porek had mentioned as part of IGNITE.

Thanks, guys.

Our next question comes from the line of Tycho Peterson with Jeffries. Please go ahead.

Hey, thanks. I want to go back to NASD. You know, the comps get easier here in the back half, so presumably double-digit growth. Could that business be double-digit for the full year or should we think about high single digit for nasd also can you talk about capacity utilization you know as we think about uh train c and d and then also biovectra phil finish and then you know third question on that is just you know with the on-shoring theme are you seeing more interest you know from pharma uh given that you know most of that business is us and then some in canada um has that kind of you know peaked uh and picked up interest from pharma companies i'm going to give that to simon yeah so as we as we think about the back end of the year and nasd and we've been saying all along that we envision high single digit growth and nudging

double digit growth i'd say there's a growing confidence that we think we can nudge that double digit growth as we look at the forecast that we're seeing begin to crystallize for q3 and q4 um and then as far as bi vector goes i think we're gonna see a sequential dip in the third quarter we're looking at some planned equipment shutdowns there and as those come online again which we anticipate in q4 provided that all goes to plan then i think we'll be back to firing on all cylinders where that's concerned as for train c and train d you know we've been through this dynamic for a while now where we were coming through the back end of the ira impacts and then we started to see our order insight really improve in 2024 that's continued through to 2025 again i think we've got pretty much all of the orders in hand now to deliver on 2025 so that utilization of train c train d is starting to become another positive tailwind driver for us now.

Yeah. And I would say we haven't seen any impact at all from potential tariffs on pharma, et cetera, reshoring or shifts at all in that business and any conversations we have with our pharma.

No changes in behavior thus far. Yeah. Watching it very closely.

Okay. And then follow up on replacement cycle. I appreciate the commentary and color you gave previously. Are you able to give us what percentage of LC systems are Infinity 3 at this point? Is it 15, 20% of the mix. And then you haven't talked much about the GC replacement cycle. You did kind of allude to that. How are you thinking about that as well?

Yeah, I mean, it's steadily grown. I mean, we're six months into the launch or a little bit more than that on the infinity tree. So it's building over time, but we don't give out the exact percentage of our install base on that one. But I can assure you it's going extremely well, Tycho.

And given what we're seeing on the cadence from our older systems and even up to the 1260 and 1290s, customers are really voting for the affinity tree when they're when they replace but i'm going to ask mike zhang here on the gc replacement cycle yeah porag definitely uh we're the leader in the gc and also gcms and we have a very large install base and we're working with our customers and i can tell you yes we have a large install base we have some you know very significant aging for this as well we're actually very excited to see some very strong momentum with our customers about you know the GC and also GCMS. If you look at our order pace, I think it's very encouraging. And we also have exciting new innovations. We just launched the new GC and we have other exciting innovations as well. What I can tell is in the next few quarters, in the next few years, we're going to see a significant opportunity coming to materialize. Thank you.

Our next question comes from the line of Brandon Coulard with Wells Fargo. Please go ahead.

Hey, thanks. Good afternoon. Bob, I saw you took down the operating cash flow guide for the year. Is that driven by tariffs and maybe inventory builds? And did you quantify the impact of currency on EPS and 2Q and then what's embedded for the full year now?

Yeah, so you're spot on. And from a cash flow perspective, that is, in fact, what we have done is looked at building inventory, which is impacting our cash flow. It's kind of a one-time activity as well as some capital equipment as well as building up. We didn't change our overall capital forecast, but there is some working capital there as well. So that's what we have. In terms of the EPS, it's close to, I'm just looking at my notes here, it's about a point or two from an EPS standpoint for the full year impact, Brandon. And we can get you the details post-call.

Okay, thanks. And, Borg, I mean, big picture, the balance sheet's very clean right now. Are you less likely to consider a larger deal right now, given the macro tariffs, interest rate volatility, or are you seeing more attractive valuations for assets? And how do you think about those trade-offs?

Yeah, I mean, we don't make any decisions based on the news that we see every, you know, every week around how we're going to deploy capital going forward. But I can say a few things. You know, we have a very, very strong list of opportunities. It's wedded in our strategy. So we've done a lot of work on that. Of course, valuations are down a little bit, but of course, we're going to remain very disciplined in what we do going forward. But I will say that M&A will become a bigger part of our story over the next few years.

Our next question comes from the line of Michael Riskin with Bank of America. Please go ahead.

Great. Thanks for taking the question guys um i'll focus both on them on the margins and sort of the cadence through the year um bobby talked a lot about the uh the impact of tariffs on 2q the 55 bps but just looking at the gross margin guide i think you know sort of not the guide but the implied numbers is kind of flat for the throughout the rest of the year maybe down 100 bps year over year so um the the implied op-em step up in 3Q and 4Q especially? Seems like it's coming a lot from the SJNA side. Could you just talk through how much of that is just, you know, whether that's volume leverage or the Ignite transformation coming through?

Yeah, hey Mike, this is Bob. Yeah, it's a little of both, as you could probably imagine. If you look at our kind of normal seasonality, kind of first half to second half, we do have a step up in margin. Some of that's related to volume. We also have more holidays and lower spending in the second half of the year. And then you've got the full impact of Ignite transformation that, before I get talked about, we talked about this $80 million of annualized, $40 million of that will happen here in the second half of the year, which will help us offset some of the tariffs. So, you're right. More of our margin improvement in the second half was actually going to show up in the OPEX because tariffs show up in the gross margin. And so, we've got some mitigation at the gross margin side, but also the mitigation activities in the OPEX side as well.

Okay. And then on the tariff side, your point on, like you just said, partially offsetting as you go through the year on the gross side, but then fully off-fitting in in 2026 so how do we think about gross margins either as a percent or whatever uh for 26 like what's the right jumping off point because you know optically you're going to have a really easy compare of 54 and a half 55 for the year but a lot of that is artificially depressed so are we going to expect like a nice gross margin jump in 26 because those offsets and that mitigation kicks in for next year?

Yeah, I would say if I could forecast what tariffs are going to be here by 26, that would be something. But that being said, if they stayed the way they are, I would expect us to be able to have an improved gross margin next year for a couple of reasons. One is exactly what you just talked about. You know, the gross will be eliminated. It's not just a mitigation. We'll eliminate it through the resourcing or reshoring of our supply chain. You'll have the benefit of volume as well. And then we also talked about the pricing capabilities that we would expect to have more price next year through price realization than we had here as a result of some of the pricing capabilities that Porig talked about. So still early days. So I don't want to, you know, we're not giving guidance here for 2026, but certainly there's some opportunities more from a tailwind perspective in gross margin going into 2026. All right. Thank you.

Our next question comes from the line of Dan Leonard with UBS. Please go ahead.

Thank you. I was hoping you could perhaps elaborate on trends you're seeing in China by end markets.

I think you mentioned industrials was down low single digits but just elsewhere between pharma environmental etc yeah so i think in in china we we've seen a pretty very stable business i mean the state except for that pull forward on us i would say that you know you see that industrials are down a little bit but pharma is pretty stable and and i would say that there's a lot of excitement i would say building in china around the second phase of the stimulus which is going to be more broader based it's actually going to be more much more broader based than it was the last time the funnels are looking extremely strong for that but i would say overall it's stable yeah i i would agree if you look across um dan uh pharma academia government um food and environmental uh and

forensics were up um diagnostics clinical our smallest market was flat and then cam was down just slightly. And some of that had to do with some of the instrumentation delays through customs that happened. Now, you may ask, well, why in China? Because actually, even though it was made in China, it has to go through a bonded warehouse, and that still has to go through customs, and it actually takes a little longer time. So no tariff impact from that standpoint, but it's still required going through customs. And so, we expect that to come back here in Q3.

Okay. Thank you. And then, Bob, a follow-up on Q3 guidance overall. It looks like the midpoint of organic revenue growth is about 2%, and that is a sequential step down from the five you just reported. I know there's some China timing issue there, but can you walk me through the main bridge factors between the Q2 result and the lower Q3 guide?

Yeah, so a couple of things. You know, I think we're taking a prudent approach given some of the still uncertainty in, you know, the tariff announcements here. I feel very good about our momentum going into Q4, excuse me, Q3. And we also have, you know, a little more difficult comp in Q3 than we have Q2. So, I wouldn't read too much into it, you know, when I look at sequential numbers in Q3 versus Q2.

Thank you very much.

Thank you.

And Mr. Ahuja, I'll turn the call back over to you.

Thanks, Regina, and thanks everyone for joining the call today. With that, we'd like to end the call. Have a good rest of the day, everyone.

This concludes today's conference call. You may now disconnect.